Investors expected a price target of -0.32 for this quarter. This rating was issued on 2/01/17. Finally, Cowen and Company cut Catabasis Pharmaceuticals from an "outperform" rating to a "market perform" rating and set a $4.00 price target on the stock.in a report on Wednesday, February 1st. Sell-side analyst recommendations point to a short term price target of $6.9 on the company shares.
When it comes to the Analysis of a Stock, Price Target plays a vital role. These analysts and investment firms use various valuation methods to decide a price target for a stock.
Considering the performance, Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) to Buy by settling a price target of $8 on 6/09/16. Catabasis Pharmaceuticals, Inc.is based in Cambridge, Massachusetts. (NASDAQ:CATB) to Outperform with a price target of $27. The Company Touched its 52-Week High on Sep 29, 2016 and 52-Week Low on Feb 1, 2017.
5 analysts projected Price Targets for Catabasis Pharmaceuticals, Inc. Sphera Funds Management LTD. boosted its position in shares of Catabasis Pharmaceuticals by 90.9% in the third quarter. (NASDAQ:CATB) a rating of 1.5 on a scale of 1 to 5. While it's Return on Investment (ROI) value is 0%. The majority of analysts covering the equity have either a Buy or Strong Buy recommendation on the stock, yielding a consensus score of 1.80. The company shares are up 23.15% from one year low and is up $0.25 since then. The analysts offering Earnings Estimates for the company were believing that Catabasis Pharmaceuticals, Inc. According to their observations and findings, the stock could provide a high EPS of $-0.32/share and a Low EPS of $-0.71/share. The difference between Actual EPS and Estimated EPS was 0.11 Percent. The U.S. digital advertising market is predictable to reach $83 billion, a boost of almost 16 percent from past year. The stock now has a Market Cap of $75.34M. The stock traded with the volume of 59.43 Million shares in the last trading session. Breaking that down further, it has performed -1.66% for the week, -6.86% for the month, -10.21% over the last quarter, -20.49% for the past half-year and -15.37% for this a year ago. Current price places the company's stock -57.69% away from its 200-day simple moving average, -35.52%, away from the 50-day average and also 33.17% away from 20-day average. Latest closing price was -22.29% below its 50-day moving average and -48.59% below its 200-day moving average.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) is now showing its ROA (Return on Assets) of -69.6%. The stock has a 1-month performance of 35.77 percent and is -53.74 percent year-to-date as of the recent close. The Monthly and Yearly performances are 64.52 percent and -68.66 percent respectively.
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company.
The Relative Volume of the company is 98.18 and Average Volume (3 months) is 605.29 million.
The stock has Return on Assets (ROA) of -69.6 percent.